Cardiovascular safety of non-steroidal anti-inflammatory drugs in chronic inflammatory rheumatic diseases

被引：5
作者：
Zavodovsky, B. V. [1 ]
Sivordova, L. E. [1 ]
机构：
[1] AB Zborovsky Res Inst Clin & Expt Rheumatol, Volgograd, Russia
来源：
TERAPEVTICHESKII ARKHIV | 2018年 / 90卷 / 08期
关键词：
cardiovascular diseases; cardiovascular risk; rheumatic diseases; rheumatoid arthritis; systemic lupus erythematosus; psoriatic arthritis; ankylosing spondylitis; chronic inflammation; non-steroidal anti-inflammatory drugs; ANKYLOSING-SPONDYLITIS; MYOCARDIAL-INFARCTION; COX-2; INHIBITORS; RISK-MANAGEMENT; ARTHRITIS; ETORICOXIB; MORTALITY; EVENTS; CELECOXIB; NAPROXEN;
D O I：
10.26442/terarkh2018908101-106
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Rheumatic diseases (RD), such as rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, psoriatic arthritis, vasculitis, gout are associated with increase in cardiovascular morbidity and mortality. The main causes of increased cardiovascular risk are inflammatory heart and vascular lesions, accelerated progression of atherosclerosis and side effects of drug therapy. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in clinical practice and are on the list of the most prescribed medications. It is known that NSAIDs have a negative effect on the cardiovascular system (CVS). However NSAIDs may decrease the intensity of inflammation, which is an independent risk risk factor for CVS pathology. Therefore in patients with RD it is theoretically possible to reduce the severity of cardiovascular side effects when using NSAIDs. The article discusses the issues of NSAID's cardiovascular safety, the molecular mechanisms underlying the negative effect of them on CVS, critically evaluated the results of main studies concerning the cardiovascular safety of NSAIDs in chronic inflammatory diseases.
引用
收藏
页码：101 / 106
页数：6
相关论文
共 65 条
  • [21] Cardiovascular disease in autoimmune rheumatic diseases
    Hollan, Ivana
    Meroni, Pier Luigi
    Ahearn, Joseph M.
    Tervaert, J. W. Cohen
    Curran, Sam
    Goodyear, Carl S.
    Hestad, Knut A.
    Kahaleh, Bashar
    Riggio, Marcello
    Shields, Kelly
    Wasko, Mary C.
    [J]. AUTOIMMUNITY REVIEWS, 2013, 12 (10) : 1004 - 1015
  • [22] Naproxen as Prophylaxis against Atrial Fibrillation after Cardiac Surgery: The NAFARM Randomized Trial
    Horbach, Stevie J.
    Lopes, Renato D.
    Guaragna, Joao C. V. da C.
    Martini, Felipe
    Mehta, Rajendra H.
    Petracco, Joao B.
    Bodanese, Luis C.
    Filho, Adauto C.
    Cirenza, Claudio
    de Paola, Angelo A. V.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2011, 124 (11) : 1036 - 1042
  • [23] [Каратеев А.Е. Karateev A.E.], 2017, [Научно-практическая ревматология, Rheumatology Science and Practice, Nauchno-prakticheskaya revmatologiya], V55, P218, DOI .org/10.14412/1995-4484-2017-218-223
  • [24] Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials
    Kearney, Patricia M.
    Baigent, Colin
    Godwin, Jon
    Halls, Heather
    Emberson, Jonathan R.
    Patrono, Carlo
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2006, 332 (7553): : 1302 - 1305
  • [25] Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system
    Kirkby, Nicholas S.
    Lundberg, Martina H.
    Harrington, Louise S.
    Leadbeater, Philip D. M.
    Milne, Ginger L.
    Potter, Claire M. F.
    Al-Yamani, Malak
    Adeyemi, Oladipupo
    Warner, Timothy D.
    Mitchell, Jane A.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (43) : 17597 - 17602
  • [26] Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study
    Kristensen, L. E.
    Jakobsen, A. K.
    Askling, J.
    Nilsson, F.
    Jacobsson, L. T. H.
    [J]. ARTHRITIS CARE & RESEARCH, 2015, 67 (08) : 1137 - 1149
  • [27] Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis
    Liao, Katherine P.
    Solomon, Daniel H.
    [J]. RHEUMATOLOGY, 2013, 52 (01) : 45 - 52
  • [28] Progress and challenges in translating the biology of atherosclerosis
    Libby, Peter
    Ridker, Paul M.
    Hansson, Goran K.
    [J]. NATURE, 2011, 473 (7347) : 317 - 325
  • [29] Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Nonselective NSAIDs in Taiwanese Patients With Rheumatoid Arthritis
    Lin, Tzu-Chieh
    Solomon, Daniel H.
    Tedeschi, Sara K.
    Yoshida, Kazuki
    Yang, Yea-Huei Kao
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (11):
  • [30] Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study
    Lindhardsen, Jesper
    Gislason, Gunnar Hilmar
    Jacobsen, Soren
    Ahlehoff, Ole
    Olsen, Anne-Marie Schjerning
    Madsen, Ole Rintek
    Torp-Pedersen, Christian
    Hansen, Peter Riis
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (08) : 1515 - 1521
1234567